中文         Site Map |
 
 

1987: We innovated artesunate. The product was authorized Chinese No.1 New Drug by SFDA.
1995: Our API product Bumetanide passed US FDA inspections and obtained API FDA approval.
1998: Our API product Levamisole Hydrochloride passed US FDA inspections and obtained API FDA approval.
2000: Our API product Levamisole Phosphate passed US FDA inspections and obtained API FDA approval.
2002: Our Artesuante tablet was listed on the Essential Drugs of WHO.
2004: Our manufacture site passed SFDA GMP inspection and obtained SFDA GMP Certificate.
2005: Our Artesuanate tablet was pre-qualified by WHO.
2007: Our anti-malarial product Arsuamoon was pre-qualified by WHO.
2008: Our arti-malarial product Arsuamoon passed USP inspection.

 

This site is published by Guilin Pharmaceutical (Shanghai) Corporation,        which is solely responsible for its content. All rights reserved.

© Guilin Pharmaceutical (Shanghai) Co., Ltd. 2017.

青海快3开奖结果今期 上海百搭怎么玩 19年大乐透走势全图 世界杯彩票比分赔率 湖南麻将秘诀 北京pk10心水论坛 5分3D规则 生肖时时彩 斯诺克比分直播g147 合赢在线配资 足球竞彩比分直播即时比分 宁夏十一选五结果 31选7中三个号有中奖吗 马戏团 足彩即时赔率 江苏十一选五走势一 5分赛车彩虹